Skip to main content
Fig. 10 | The Journal of Headache and Pain

Fig. 10

From: Therapeutic novelties in migraine: new drugs, new hope?

Fig. 10

Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with galcanezumab. A darker bar indicates a higher dose. *EVOLVE-1; 120 mg vs. placebo, p < 0.001; 240 mg vs. placebo, p < 0.001. EVOLVE-2; 120 mg vs. placebo, p < 0.001; 240 mg vs. placebo, p < 0.001

Back to article page
\